Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Pharmaxis Ltd ( (AU:SNT) ) is now available.
Pharmaxis Ltd recently participated in the E&P 4th Annual Small Cap Healthcare Conference, where CEO Gary Phillips discussed the company’s strategic initiatives. The announcement highlighted the potential impact of Syntara’s product pipeline on Pharmaxis’s future financial position, emphasizing the inherent risks and uncertainties involved in product development and commercialization.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Average Trading Volume: 7,384,225
Technical Sentiment Signal: Sell
Current Market Cap: A$40.81M
For a thorough assessment of SNT stock, go to TipRanks’ Stock Analysis page.